Physician profile
Luis Chu
NPI 1336130046
$14,504.35
in general payments reported to CMS, 2019-2025
71 companies · $3,487 in 2025
The $3,487 reported for 2025 was more than what a typical Medical Oncology provider received nationally (typical 2025 total: $1,158).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,109 · 2020: $230 · 2022: $916 · 2023: $4,751 · 2024: $3,011 · 2025: $3,487.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $11K.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $11,248.57 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Exelixis INC. | $1,588.15 | 2019-2025 | Cabometyx |
| Merck Sharp & Dohme LLC | $1,177.31 | 2019-2025 | Keytruda, Lynparza, Keytruda Qlex |
| Pfizer INC. | $909.54 | 2019-2025 | |
| Celgene Corporation | $771.20 | 2019-2025 | Reblozyl, Pomalyst, Opdualag |
| Janssen Biotech, INC. | $760.42 | 2019-2025 | Tecvayli, Darzalex, Talvey |
| Novartis Pharmaceuticals Corporation | $742.37 | 2019-2025 | |
| E.R. Squibb & Sons, L.L.C. | $686.00 | 2019-2025 | Opdivo, Opdualag |
| Gilead Sciences, INC. | $557.80 | 2019-2025 | Trodelvy |
| Takeda Pharmaceuticals U.S.A., INC. | $473.99 | 2023-2025 | Fruzaqla, Ninlaro, Hyqvia |
| Genentech USA, INC. | $453.44 | 2019-2024 | Lunsumio, Tecentriq, Polivy |
| Glaxosmithkline, LLC. | $443.77 | 2023-2025 | Ojjaara, Shingrix, Zejula |
| Daiichi Sankyo INC. | $415.54 | 2022-2025 | Enhertu, Datroway |
| Abbvie INC. | $412.11 | 2019-2025 | Venclexta |
| Adaptive Biotechnologies Corporation | $388.46 | 2023-2025 | Clonoseq |
| Incyte Corporation | $327.70 | 2022-2025 | Monjuvi, Jakafi, Niktimvo |
Show all 71 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Genzyme Corporation | $311.82 | 2019-2025 | |
| Beigene USA, INC. | $277.04 | 2022-2025 | Brukinsa |
| Astellas Pharma US INC | $275.38 | 2019-2025 | Padcev, Xospata, Vyloy |
| Astrazeneca Pharmaceuticals Lp | $272.50 | 2023-2025 | Enhertu, Imfinzi, Lynparza |
| Array Biopharma INC | $224.28 | 2019-2025 | Braftovi, Lorbrena, Mektovi |
| Regeneron Healthcare Solutions, INC. | $209.85 | 2019-2025 | Lynozyfic, Libtayo |
| Seagen INC. | $209.49 | 2020-2023 | Padcev, Tukysa, Adcetris |
| Lilly USA, LLC | $201.49 | 2019-2023 | Jaypirca |
| Pharmacyclics LLC, An Abbvie Company | $157.00 | 2022-2023 | Imbruvica |
| Jazz Pharmaceuticals INC. | $128.82 | 2019-2025 | |
| Tersera Therapeutics LLC | $128.79 | 2019-2025 | Quzyttir, Zoladex |
| Rigel Pharmaceuticals, INC. | $127.65 | 2019-2023 | Tavalisse, Rezlidhia |
| Eisai INC. | $119.41 | 2023-2025 | |
| Pharmaessentia USA Corporation | $117.03 | 2023-2025 | Besremi |
| Taiho Oncology, INC. | $98.74 | 2024-2025 | |
| Sumitomo Pharma America, INC. | $88.94 | 2023-2025 | Orgovyx |
| Mirati Therapeutics, INC. | $87.16 | 2023-2024 | Krazati |
| Amgen INC. | $86.05 | 2019-2022 | |
| Recordati_rare_diseases_inc. | $83.10 | 2022-2025 | Enjaymo, Panhematin, Sylvant |
| Dendreon Pharmaceuticals LLC | $81.39 | 2022-2024 | Provenge |
| Genentech, INC. | $79.90 | 2019 | |
| G1 Therapeutics, INC. | $76.46 | 2022-2023 | Cosela |
| Legend Biotech USA INC. | $75.09 | 2025 | Carvykti |
| Aveo Pharmaceuticals, INC. | $69.96 | 2023-2025 | Fotivda |
| Puma Biotechnology, INC. | $69.69 | 2019-2025 | |
| Kite Pharma, INC. | $63.79 | 2022-2024 | Yescarta |
| Bayer Healthcare Pharmaceuticals INC. | $52.29 | 2022-2025 | |
| Ipsen Biopharmaceuticals, INC | $47.67 | 2019-2025 | Onivyde |
| Alexion Pharmaceuticals, INC. | $46.86 | 2023-2024 | Ultomiris |
| Beone Medicines USA, INC. | $43.05 | 2025 | Brukinsa |
| Morphosys, US INC. | $35.59 | 2023 | Monjuvi |
| Iovance Biotherapeutics, INC. | $32.29 | 2025 | Amtagvi |
| Emd Serono, INC. | $30.20 | 2019-2024 | |
| Helsinn Therapeutics (U.S.), INC. | $29.84 | 2019 | |
| Adc Therapeutics America, INC. | $27.11 | 2022-2024 | |
| Spectrum Pharmaceuticals INC. | $23.96 | 2023 | Rolvedon |
| Geron Corporation | $22.42 | 2025 | Rytelo |
| Springworks Therapeutics, INC. | $22.30 | 2025 | Ogsiveo |
| Servier Pharmaceuticals LLC | $22.22 | 2024 | |
| Pharmacosmos Therapeutics INC. | $20.04 | 2025 | Monoferric |
| Eusa Pharma (US) LLC | $19.52 | 2022 | |
| Cti Biopharma Corp. | $17.88 | 2023 | Vonjo |
| Deciphera Pharmaceuticals INC. | $17.60 | 2024 | Tgct, Qinlock |
| Boehringer Ingelheim Pharmaceuticals, INC. | $17.45 | 2022 | |
| Sobi, INC | $17.00 | 2023 | |
| Blueprint Medicines Corporation | $16.57 | 2020 | |
| Karyopharm Therapeutics INC. | $16.24 | 2024 | Xpovio |
| Novocure INC. | $16.01 | 2025 | Optune Lua (Novottf-200t) |
| Shire North American Group INC | $16.01 | 2019 | |
| Janssen Pharmaceuticals, INC | $14.78 | 2019 | |
| Apellis Pharmaceuticals, INC. | $13.48 | 2023 | Empaveli |
| Agios Pharmaceuticals, INC. | $13.06 | 2019 | |
| Menarini Silicon Biosystems, INC. | $12.36 | 2023 | Cellsearch |
| Pharmaand Gmbh | $6.84 | 2025 | Rubraca |
| Fortovia Therapeutics, INC. | $4.61 | 2019 | |
| Veracyte, INC. | $0.48 | 2020 |
Drugs and devices associated with these payments
Cabometyx $1,524Keytruda $819Reblozyl $524Enhertu $499Imbruvica $404Clonoseq $388Padcev $379Ojjaara $346Tecvayli $303Opdivo $297Trodelvy $296Darzalex $283Fruzaqla $275Brukinsa $272Pluvicto $251Tukysa $241Orgovyx $193Monjuvi $192Lynparza $184Ibrance $183Talvey $181Xtandi $177Epkinly $161Braftovi $161Inlyta $156Lorbrena $153Talzenna $143Lunsumio $139Opdualag $139Adcetris $135Mektovi $131Elrexfio $128Venclexta $127Lenvima $119Besremi $117Jakafi $112Ninlaro $102Lonsurf $98.74Inqovi $98.74Kisqali $92.47Imfinzi $90.77Tavalisse $89.63Rezlidhia $89.63Krazati $87.16Xalkori $81.26Zepzelca $76.77Enjaymo $76.58Carvykti $75.09Fotivda $69.96Provenge $68.60Pomalyst $67.89Shingrix $66.79Emrelis $64.99Bosulif $64.23Sarclisa $61.70Cosela $58.31Jaypirca $55.91Quzyttir $55.76Keytruda Qlex $54.58Tecentriq $54.52Hyqvia $51.95Fabhalta $46.92Ultomiris $46.86Cablivi $46.37Polivy $45.83Yescarta $45.58Xospata $42.90Zoladex $39.29Datroway $38.99Comirnaty $38.81Tivdak $38.15Rozlytrek $36.51Gavreto $36.51Alecensa $36.51Nerlynx $36.12Bavencio $32.52Amtagvi $32.29Vyloy $31.10Jemperli $30.82Zejula $30.82Onivyde $30.45Lynozyfic $25.46Alunbrig $24.50Rolvedon $23.96Niktimvo $23.90Nubeqa $23.73Elahere $22.72Ziihera $22.51Rytelo $22.42Ogsiveo $22.30Scemblix $20.80Vonvendi $20.70Panhematin $20.49Monoferric $20.04Libtayo $19.93Avastin $19.78Tabrecta $19.67Promacta $19.32Vonjo $17.88Pemazyre $17.75
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Luis Chu listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.